1Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care(BSC)vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality ot hie as the primary outcome. U-K NSCLC Gemcitabine Group. Non- Small Cell Lung Cancer [ J ]. Br J Cancer, 2000, 83 (4) :447 - 453.
2[No authors listed] Effects of vinorelbine on quality of life and survival of elderly patients with advanced non - small - cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group [J]. J Natl Cancer Inst,1999,91(1) :66 - 72.
3Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non - small - cell lung cancer previously treated with platinum - based chemotherapy [ J ]. J Clin Oncol, 2000,18(10) :2095 - 2103.
4Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non- small - cell lung cancer [J]. J Natl Cancer Inst, 2000,92(13) : 1074 - 1080.
5[ No authors listed ] Chemotherapy in non - small cell lung cancer: a meta- analysis using updated data on individual patients from 52 randomised clinical trials. Non - small Cell Lung Cancer Collaborative Group [ J ]. BMJ, 1995, 311 (7010) :899- 909.
6Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or ⅢA non - small - cell lung cancer. Eastem Cooperative Oncology Group [J]. N Engl J Med, 2000, 343(17) :1217-1222.
7Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or ⅢA non-small-cell lung cancer [J]. J Natl Cancer Inst,2003,95(19) :1453 - 1461.
8Le Chevalier T. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin - based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small-cell lung Cancer (NSCLC) [J]. Proc Am Soc Clin Oncol, 2003, (abstr. 6) : 1423 - 1425.
10Aiello RJ, Brees D, Bourassa PA, et al, Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages [J ]. Arterioscler Thromb Vasc Biol,2002,22(4) :630 - 637.
二级参考文献20
1[2]Tang GL, Huang SL, Yien HW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection[J]. Crit Care Med, 2000, 28(7):2733-2736
2[3]Sun KH, Yu CL, Tang SJ et al. Monoclonal anti-double -stranded DNA autoantibody stimulates the expression and release IL-1, IL-6, IL-8, IL-10 and TNF alpha from normal human mononuclear cells involving in the lupus pathogenesis[J]. Immunology, 2000,99(3):352-360.
3[4]Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α induced cell death[J]. Science, 1996,274(5288): 782-784.
4MountainCF.Revisions in the International System for Staging Lung Cancer.Chest,1997,111:1710-1717.
5Mountain CF,McMurtrey MJ,Frazier OH.Current results of surgical treatment for lung cancer.Cancer Bull,1980,32:105-108.
6Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials.Non-small Cell Lung Cancer Collaborative Group.BMJ,1995,311:899-909.
7Keller SM,Adak S,Wagner H,et al.A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or Ⅲ A non-small-cell lung cancer.Eastern Cooperative Oncology Group.N Engl J Med,2000,343:1217-1222.
8Scagliotti GV,Fossati R,Torri V,et al.Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ,Ⅱ,or ⅢA non-small-cell lung cancer.J Natl Cancer Inst,2003,95:1453-1461.
9Fisher MD,D' Orazio A.Phase Ⅱ and Ⅲ trials:comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594)[J].Clin Lung Cancer,2000,2(1):21-22.
4Siegel R, Naishadlmm D, Jemal A. Cancer statistics [J]. CA Cancer J Clin, 2012, 62(I): I0-29.
5Jahangeer S, Forde P, Soden D, et al. Review of current thermal ab- lation treatment for lung cancer and the potential of electrochemo- therapy as a means for treatment of lung tumours [J]. Cancer Treat Rev, 2013, 39(8): 862-871.
6Ierardi AM, Floridi C, Fontana F, et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequeney ablation [J]. Radiol Med, 2013, 118(6): 949-961.
7Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases [J]. Eur J Gaslroenterol Hepatol, 2013, 25(4): 442-446.
8Baisi A, De Simone M, Raveglia F, et al. Thermal ablation in the treatment of lung cancer: present and future [J]. Eur J Cardiothorae Surg, 2013, 43(4): 683-686.
9Abbas G, Pennathur A, Landreneau R J, et al. Radiofrequency and microwave ablation ofhmg tumors [J]. J Surg Oncol, 2009, 100(8): 645-650.
10Fernarido HC, De Hoyos A, Landrencan ILl, et al. Radiofi'equency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates [J]. J Thorac Cardiovasc Surg, 2005, 129(3): 639-644.
